bioRxiv Science⌕ Search

Biology subjects

Momjian, S.

Publications and source records attributed to Momjian, S..

2 recordsLinked to original sources

How well does electrical source imaging reconstruct neural time series? Evidence from simultaneous scalp and intracranial EEG recordings

Electrical source imaging (ESI) estimates neural activity from scalp EEG, but its ability to reconstruct the temporal dynamics of spontaneous brain activity beyond source localization remains unclear. This is assessed using simultaneous high-density EEG and intracranial EEG (iEEG) recordings during spontaneous activity in 34 patients with drug-resistant focal epilepsy. Four ESI approaches (three distributed source models and one beamformer) are applied to estimate neural activity, which is then projected onto iEEG electrode locations to generate virtual iEEG signals for comparison with measured recordings. Reconstruction fidelity is quantified using Pearson correlations between actual and virtual iEEG signals, while spatial accuracy is assessed through peak localization error and spatial deviation derived from point-spread and cross-talk functions. Analyses are performed in broadband and delta, theta, alpha, and beta bands. Temporal reconstruction remains limited, with the highest estimated correlation reaching 0.126, localization errors of approximately 3 cm, and substantial spatial leakage. Reconstruction quality decreases with electrode depth and increasing frequency, while improving with higher epileptic spike rates. No single method is optimal across all metrics, although beamforming shows the weakest temporal reconstruction. These findings indicate that ESI only partially captures spontaneous intracranial dynamics and define spatial and temporal constraints for interpreting EEG-based source reconstructions.

neuroscience↗

PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma

The great success of chimeric antigen receptor (CAR)-T cell therapy in B-cell malignancies has prompted its translation to solid tumors. In the case of glioblastoma (GBM), clinical trials have shown modest efficacy, but anti-GBM CAR-T cells are being intensely developed. In this study, we selected PTPRZ1 as an attractive new target for GBM treatment. We isolated six anti-human PTPRZ1 scFv from a human phage display library and produced 2nd generation CAR-T cells in an RNA format. Patient-derived GBM PTPRZ1-knock-in cell lines were used to select the CAR construct (471_28z), which showed high cytotoxicity while consistently displaying high CAR expression. CAR-T cells incorporating 471_28z were able to release IFN-{gamma}, IL-2, TNF-, Granzyme B, IL-17A, IL-6, and soluble FasL, and displayed low tonic signaling. Additionally, they maintained an effector memory phenotype after in vitro killing. Importantly, 471_28z CAR-T cells displayed strong bystander killing against PTPRZ1-negative cell lines after pre-activation by PTPRZ1-positive tumor cells, but did not kill antigen-negative non-tumor cells. In an orthotopic xenograft tumor model using NSG mice, a single dose of anti-PTPRZ1 CAR-T cells significantly delayed tumor growth. Taken together, these results validate the use of PTPRZ1 as a new GBM target and prompt the use of anti-PTPRZ1 CAR-T cells for clinical translation.

immunology↗